ArticleCancer medicine2016

Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.

Vasilios Liapis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.